SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (Including Cervical, Urothelial, Ovarian, and Prostate Cancer)
Phase: 2
Status: Ongoing
About
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (Including Cervical, Urothelial, Ovarian, and Prostate Cancer)
Details
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Sponsor: Klus Pharma Inc
NCT 05642780
